Dr. Burstein on Adjuvant Endocrine Therapy for ER+ Breast Cancer

Video

Harold J. Burstein, MD, PhD, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses adjuvant endocrine therapy for postmenopausal women with ER-positive breast cancer.

Harold J. Burstein, MD, PhD, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses adjuvant endocrine therapy for postmenopausal women with estrogen receptor (ER)-positive breast cancer.

Adjuvant endocrine therapy is the standard for most women who have ER-positive early stage breast cancer. But, for postmenopausal women with ER-positive breast cancer, treatment has historically been tamoxifen or an aromatase inhibitor. Aromatase inhibitors have been shown to have a slight advantage, says Burstein, specifically in women who have higher-risk biologies.

Anti-estrogen therapy remains a critical therapy for postmenopausal women with ER-positive breast cancer, and progress is being made regarding drug selection and duration of treatment, Burstein adds.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "